论文部分内容阅读
目的探讨不同剂量依达拉奉用于治疗缺血性脑血管病疗效。方法选择2013年2月—2014年2月该院收治的缺血性脑血管病患者84例,随机分为小剂量和大剂量二组,每组各42例。小剂量组给予60mg/d依达拉奉进行治疗,大剂量组给予120mg/d依达拉奉进行治疗。对二组患者治疗后的神经功能缺损评分、Barthel指数、总有效率及不良反应发生率进行比较。结果 1治疗后小剂量组与大剂量组的神经功能缺损评分均明显低于治疗前,差异具有统计学意义(P<0.05);治疗后小剂量组与大剂量组的神经功能缺损评分相比较,差异无统计学意义(P>0.05)。2治疗后小剂量组与大剂量组的Barthel指数均明显高于治疗前,差异具有统计学意义(P<0.05);治疗后小剂量组与大剂量组的Barthel指数相比较,差异无统计学意义(P>0.05)。3治疗后小剂量组的总有效率(78.6%)与大剂量组(71.4%)相比较,差异无统计学意义(P>0.05)。4治疗后小剂量组的不良反应发生率(4.8%)明显低于大剂量组(26.1%),差异具有统计学意义(P<0.05)。结论对缺血性脑血管病患者,小剂量依达拉奉与大剂量依达拉奉在改善患者神经功能,提高日常活动能力及总有效率方面效果相当,但小剂量依达拉奉治疗所产生的不良反应相对较少,具有较高的安全性,值得临床推广与应用。
Objective To investigate the efficacy of different doses of edaravone in the treatment of ischemic cerebrovascular disease. Methods Eighty-four patients with ischemic cerebrovascular disease admitted to our hospital from February 2013 to February 2014 were randomly divided into two groups: small dose and high dose, 42 patients in each group. Low-dose group was given 60mg / d edaravone for treatment, and high-dose group was given 120mg / d edaravone for treatment. The neurological deficit score, Barthel index, total effective rate and incidence of adverse reactions in the two groups were compared. Results After treatment, the scores of neurological deficits of low-dose group and high-dose group were significantly lower than those before treatment (P <0.05); after treatment, the neurological deficit scores of low-dose group and high-dose group were significantly , The difference was not statistically significant (P> 0.05). After treatment, Barthel index of low-dose group and high-dose group were significantly higher than before treatment, the difference was statistically significant (P <0.05); after treatment, Barthel index of low-dose group and high-dose group had no statistical difference Significance (P> 0.05). 3 After treatment, the total effective rate of small dose group (78.6%) and high dose group (71.4%), the difference was not statistically significant (P> 0.05). 4 The incidence of adverse reactions in the low-dose group (4.8%) was significantly lower than that in the high-dose group (26.1%), the difference was statistically significant (P <0.05). Conclusion In patients with ischemic cerebrovascular disease, low-dose edaravone and high-dose edaravone are effective in improving neurological function, improving daily activities and total effective rate, but low-dose edaravone treatment The adverse reaction is relatively less, with higher safety, it is worth clinical promotion and application.